Bristol Myers Squibb Company $BMY Holdings Lifted by Integrity Alliance LLC.

Integrity Alliance LLC. grew its position in Bristol Myers Squibb Company (NYSE:BMY) by 314.0% in the 4th quarter, Holdings Channel.com reports. The firm owned 37,376 shares of the biopharmaceutical company’s stock after buying an additional 28,348 shares during the period. Integrity Alliance LLC.’s holdings in Bristol Myers Squibb were worth $2,016,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Arvest Bank Trust Division boosted its holdings in shares of Bristol Myers Squibb by 7.2% in the fourth quarter. Arvest Bank Trust Division now owns 13,053 shares of the biopharmaceutical company’s stock valued at $704,000 after acquiring an additional 875 shares in the last quarter. Cary Street Partners Investment Advisory LLC boosted its holdings in shares of Bristol Myers Squibb by 19.2% in the fourth quarter. Cary Street Partners Investment Advisory LLC now owns 5,582 shares of the biopharmaceutical company’s stock valued at $301,000 after acquiring an additional 901 shares in the last quarter. Smithfield Trust Co boosted its holdings in shares of Bristol Myers Squibb by 18.4% in the fourth quarter. Smithfield Trust Co now owns 18,319 shares of the biopharmaceutical company’s stock valued at $990,000 after acquiring an additional 2,841 shares in the last quarter. Bleakley Financial Group LLC boosted its holdings in shares of Bristol Myers Squibb by 16.4% in the fourth quarter. Bleakley Financial Group LLC now owns 33,343 shares of the biopharmaceutical company’s stock valued at $1,799,000 after acquiring an additional 4,698 shares in the last quarter. Finally, Wellington Shields Capital Management LLC boosted its holdings in shares of Bristol Myers Squibb by 127.6% in the fourth quarter. Wellington Shields Capital Management LLC now owns 12,498 shares of the biopharmaceutical company’s stock valued at $674,000 after acquiring an additional 7,006 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors.

Bristol Myers Squibb Trading Down 0.7%

Shares of NYSE:BMY opened at $57.63 on Thursday. The stock has a market capitalization of $117.68 billion, a price-to-earnings ratio of 16.19, a PEG ratio of 0.17 and a beta of 0.26. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $62.89. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42. The company has a 50 day moving average price of $58.42 and a 200 day moving average price of $56.18.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, topping analysts’ consensus estimates of $1.42 by $0.16. The firm had revenue of $11.49 billion during the quarter, compared to analysts’ expectations of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The firm’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period last year, the firm posted $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, research analysts anticipate that Bristol Myers Squibb Company will post 6.31 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, May 1st. Investors of record on Thursday, April 2nd were issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 4.4%. The ex-dividend date was Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 70.79%.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Royal Bank Of Canada assumed coverage on shares of Bristol Myers Squibb in a report on Tuesday, February 24th. They issued a “sector perform” rating and a $60.00 price objective for the company. Wells Fargo & Company reiterated an “outperform” rating and issued a $60.00 price objective (up from $55.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. Piper Sandler reiterated an “overweight” rating and issued a $75.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, February 23rd. Cantor Fitzgerald increased their price objective on shares of Bristol Myers Squibb from $45.00 to $54.00 and gave the company a “neutral” rating in a report on Wednesday, April 8th. Finally, Guggenheim reiterated a “buy” rating and issued a $72.00 price objective on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Eight research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $61.31.

Insiders Place Their Bets

In related news, EVP David V. Elkins sold 30,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the sale, the executive vice president directly owned 159,248 shares in the company, valued at approximately $9,820,824.16. This trade represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 0.05% of the company’s stock.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.